Search - tctmd.com

Displaying 121 - 140 of 382

Sort: Relevancy | Date

Presentation

Effect of Sex Differences on Invasive Measures of Coronary Microvascular Dysfunction in Pts With Angina in the Absence of Obstructive CAD

Presenter: Y. Kobayashi

September 22, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Daily News

Registry Charts Trends in Mechanical Circulatory Support During PCI

L.A. McKeown

September 14, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

News Industry News

TriVascular Technologies raises $10m, launches study of EVAR in women

August 24, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Daily News

Subestudio del COURAGE: La PCI No Ofrece Beneficio Añadido sobre, Solo, el Tratamiento Médico Óptimo, ni en Hombres ni en Mujeres

L.A. McKeown

August 03, 2015

News Daily News

COURAGE 亚组研究：合并 PCI 并不会改善单纯行 OMT 治疗的女性或男性患者的总体疗效

L.A. McKeown

August 03, 2015

News Daily News

COURAGE Substudy: PCI Adds No Overall Benefit to OMT Alone in Either Women or Men

L.A. McKeown

August 03, 2015

Presentation

COURAGE Substudy: OMT With or Without PCI in Women With Stable Coronary Disease

Presenter: S. Acharjee

July 31, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Featured Fellow

Kimberly Atianzar, MD

Yael L. Maxwell

July 20, 2015

Advertisement

Effect of Sex Differences on Invasive Measures of Coronary Microvascular Dysfunction in Pts With Angina in the Absence of Obstructive CAD

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Registry Charts Trends in Mechanical Circulatory Support During PCI

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

TriVascular Technologies raises $10m, launches study of EVAR in women

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Subestudio del COURAGE: La PCI No Ofrece Beneficio Añadido sobre, Solo, el Tratamiento Médico Óptimo, ni en Hombres ni en Mujeres

COURAGE 亚组研究：合并 PCI 并不会改善单纯行 OMT 治疗的女性或男性患者的总体疗效

COURAGE Substudy: PCI Adds No Overall Benefit to OMT Alone in Either Women or Men

COURAGE Substudy: OMT With or Without PCI in Women With Stable Coronary Disease

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Kimberly Atianzar, MD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content